Company news

Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A (SSE:600196) news

Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: (600196)"Shanghai Fosun Pharmaceutical (Group) Co.…

Shanghai Fosun Pharmaceutical (group) Co., Ltd. Class A (SSE:600196) news

Press releases & updates

(600196)"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Results of Reserved Grant under the 2025 A-Share Stock Option Incentive Plan

A New International Medical Approach Aimed at Reversing Diabetes has Officially Launched in Shenzhen, China

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Signing of Cooperation and License Agreement by Controlled Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Release of Pledge of Certain Shares Held by Shareholder

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Pledge and Release of Pledge on Certain Shares Held by a Shareholder

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Acceptance of the Drug Registration Application of Controlled Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on the Public Disclosure and Review Opinion of the List of Participants for the Reserved Grant under the 2025 A-Share Stock Option Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Extension of Loans to a Controlled Subsidiary and Related Party Transaction

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on a Controlled Subsidiary's Drug Obtaining Registration Approval for a New Indication

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Reserved Grant of the 2025 H-Share Restricted Share Unit Plan

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Indicative Announcement on Obtaining Registration Approval for the Licensed Drug

Fosun Pharma Announces 2026 Interim Results

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Progress of the Drug Clinical Trial of a Controlled Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Progress in Providing Guarantee for Controlled Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Receipt of Drug Registration Approval by a Controlled Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Completion of Private Investment Fund Filing for the Investment Fund Established with the Company's Participation as an Investor

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Controlled Subsidiary's Drug Obtaining Approval for Clinical Trial

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Release of Pledge of Certain Shares of Shareholder

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Implementation of A-Share Dividend Distribution for 2025

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Pledge of Partial Shares Held by a Shareholder

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Progress in Providing Guarantee for Holding Subsidiary

"Shanghai Fosun Pharmaceutical (Group) Co., Ltd."Announcement on Resolutions of the 33rd (Extraordinary) Meeting of the 10th Board of Directors

Announcement on Progress in Transfer of Partnership Interests and Progress in Private Equity Investment Fund Invested by the Partnership

Indicative Announcement on Obtaining EU Approval of a New Indication for a Drug Developed by the Holding Subsidiary

Announcement on Progress in Providing Guarantee for Holding Subsidiary

Announcement on Holding Subsidiary's Passing GMP Compliance Inspection

Announcement on Resolutions of the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026

Announcement on New Drug Indication Obtaining Registration Approval for a Holding Subsidiary

Indicative Announcement on Convening the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026

Announcement on Obtaining Approval of Drug Registration by the Holding Subsidiary

Announcement on Progress in Participating in Setting up Private Equity Investment Fund

Announcement on Outward Investment and Related Party Transactions

Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial

Announcement on Acceptance of Drug Registration Application of Holding Subsidiary

Notice on Convening the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026

Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial from FDA

Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework

Announcement on Progress in Participation in Establishing a Private Equity Investment Fund and Proposed Disposal of Assets

Announcement on the Pledge of Partial Shares Held by Shareholders

Announcement on Approval of Supplementary Drug Application by Holding Subsidiary

Announcement on Change of Chief Financial Officer

Announcement on Participating in Setting up Private Equity Investment Fund

Announcement on Proposed Expansion of Financial Leasing Business by a Holding Subsidiary

Announcement on Resolutions of the Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share General Meeting

Self-Inspection Report on Trading of the Company's Shares by Insiders Related to the Spin-off and Listing of a Subsidiary on the Main Board of the Stock Exchange of Hong Kong Limited

Indicative Announcement on Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share General Meeting

Announcement on Progress in Signing the Licensing Agreement of Wholly-owned Subsidiary

Announcement on Signing License Agreement by Holding Subsidiary